États-Unis · Bourse & Finance · Yahoo Finance

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound

Publié par Yahoo Finance · États-Unis il y a 8 h

Continue » Eli Lilly's Zepbound is currently the leading medicine in the anti-obesity market largely because it is more effective than its main competitor, Novo Nordisk 's (NYSE:…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound

À lire aussi

David Robinson says a sense of 'cognitive dissonance' led him to leave OpenAI

The 5 most expensive basketball cards ever sold

Wall Street closed in the red as investors focused on yields and the Fed minutes

Global Diesel Crunch Fuels New Wave of Energy Nationalism

Tether Signs Deal With Kazakhstan's Central Bank to Explore a Stablecoin and Tokenized Assets

Apollo, banks in talks to finance SpaceX's $40 billion Nvidia GPU purchase

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound

Partager

À lire aussi

David Robinson says a sense of 'cognitive dissonance' led him to leave OpenAI

The 5 most expensive basketball cards ever sold

Wall Street closed in the red as investors focused on yields and the Fed minutes

Global Diesel Crunch Fuels New Wave of Energy Nationalism

Tether Signs Deal With Kazakhstan's Central Bank to Explore a Stablecoin and Tokenized Assets

Apollo, banks in talks to finance SpaceX's $40 billion Nvidia GPU purchase